Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 3/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986936 | 0.86 | PIK3CD (0.42) | MAP4K4F12P2RX7 | |
| SCHEMBL4984698 | 0.84 | F12 (0.42) | F12P2RX7 | |
| SCHEMBL4988247 | 0.84 | RIPK1 (0.40) | P2RX7 | |
| SCHEMBL4982842 | 0.81 | MAP4K4 (0.40) | MAP4K4P2RX7 | |
| SCHEMBL4985073 | 0.81 | PTGDR2 (0.37) | F12P2RX7 | |
| SCHEMBL4980900 | 0.81 | P2RX3 (0.39) | P2RX7 | |
| SCHEMBL4988613 | 0.81 | CGAS (0.40) | NOTUMP2RX7 | |
| SCHEMBL19959250 | 0.81 | ADORA1 (0.49) | MAP4K4F12MAPT | |
| SCHEMBL4990817 | 0.80 | PKM (0.46) | P2RX7MAPT | |
| SCHEMBL4988444 | 0.79 | KEAP1 (0.46) | MAP4K4P2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | MAP4K4 1256/4885BPTF 2605/4885NOTUM 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.